Related Experiment Video
Updated: Nov 17, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway
1Department of Computer Science, Hunter College, The City University of New York, New York, United States of America.
Abstract:
Drug combinations have demonstrated great potential in cancer treatments. They alleviate drug resistance and improve therapeutic efficacy. The fast-growing number of anti-cancer drugs has caused the experimental investigation of all drug combinations to become costly and time-consuming. Computational techniques can improve the efficiency of drug combination screening. Despite recent advances in applying machine learning to synergistic drug combination prediction, several challenges remain. First, the performance of existing methods is suboptimal. There is still much space for improvement. Second, biological knowledge has not been fully incorporated into the model. Finally, many models are lack interpretability, limiting their clinical applications. To address these challenges, we have developed a knowledge-enabled and self-attention transformer boosted deep learning model, TranSynergy, which improves the performance and interpretability of synergistic drug combination prediction. TranSynergy is designed so that the cellular effect of drug actions can be explicitly modeled through cell-line gene dependency, gene-gene interaction, and genome-wide drug-target interaction. A novel Shapley Additive Gene Set Enrichment Analysis (SA-GSEA) method has been developed to deconvolute genes that contribute to the synergistic drug combination and improve model interpretability. Extensive benchmark studies demonstrate that TranSynergy outperforms the state-of-the-art method, suggesting the potential of mechanism-driven machine learning. Novel pathways that are associated with the synergistic combinations are revealed and supported by experimental evidences. They may provide new insights into identifying biomarkers for precision medicine and discovering new anti-cancer therapies. Several new synergistic drug combinations have been predicted with high confidence for ovarian cancer which has few treatment options. The code is available at https://github.com/qiaoliuhub/drug_combination.
Insights
We developed TranSynergy, a deep learning model that predicts synergistic drug combinations for cancer treatment. It incorporates biological knowledge for improved accuracy and interpretability, aiding precision medicine and new therapy discovery.
Area of Science:
- Computational biology
- Machine learning in oncology
- Drug discovery and development
Background:
- Drug combinations offer improved cancer therapeutic efficacy and reduced resistance.
- Experimental screening of all potential anti-cancer drug combinations is costly and time-consuming.
- Current machine learning models for synergistic drug prediction face limitations in performance, biological knowledge integration, and interpretability.
Purpose of the Study:
- To develop an advanced deep learning model for predicting synergistic drug combinations.
- To enhance the performance and interpretability of synergistic drug combination prediction.
- To integrate biological knowledge and mechanism-driven insights into predictive models.
Main Methods:
- Developed TranSynergy, a knowledge-enabled, self-attention transformer-boosted deep learning model.
- Incorporated cellular effects via cell-line gene dependency, gene-gene interactions, and drug-target interactions.
- Introduced Shapley Additive Gene Set Enrichment Analysis (SA-GSEA) for gene contribution deconvolution and interpretability.
Main Results:
- TranSynergy significantly outperforms state-of-the-art methods in synergistic drug combination prediction.
- The model successfully identified novel pathways associated with synergistic combinations, supported by experimental evidence.
- High-confidence synergistic drug combinations were predicted for ovarian cancer.
Conclusions:
- Mechanism-driven machine learning, as exemplified by TranSynergy, shows significant potential in advancing cancer drug discovery.
- The model's interpretability offers new insights for identifying precision medicine biomarkers and novel anti-cancer therapies.
- TranSynergy provides a powerful computational tool for efficient drug combination screening, particularly for challenging cancers like ovarian cancer.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Predicting Reaction Outcomes
Drug Discovery: Overview
Agonism and Antagonism: Quantification
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

